Corrigendum
1. Shijiazhuang Yiling Pharmaceutical Co., Ltd. provided part of the funding (accounting for 10.41%) and donated the study drugs (Lianhua Qingwen capsules, equivalent to CNY 29,600) for this research, but had no role in the data acquisition, statistical analysis and writing of this article.
2. The corresponding author, Dr. Zhen-hua Jia is the son-in-law of Yiling Wu, who is the founder of the study drug manufacturer, Shijiazhuang Yiling Pharmaceutical Co., Ltd.
3. Shijiazhuang Yiling Pharmaceutical Co., Ltd. and Hebei Yiling Hospital are two independent legal entities.
4. Shijiazhuang Yiling Pharmaceutical Co., Ltd. and Yiling Collateral Disease Company, as sibling companies both under the control of Yiling Pharmaceutical Technology Co., Ltd, are two completely independent legal entities.
5. This clinical trial was registered at the Chinese Clinical Trial Registry (https://www.chictr.org.cn) by Mr. Shuolong Han (applicant), an employee of Shijiazhuang Yiling Pharmaceutical Co., Ltd.
6. A total of 284 patients with Covid-19 were enrolled from 23 hospitals located in nine provinces throughout mainland China. No hospital enrolled more than 17% cases of the studied population. Also, no patient was enrolled at the Hebei Yiling Hospital, where the corresponding author, Dr Zhen-hua Jia, is working.
7. The corresponding author, Dr. Zhen-hua Jia, as the leader of Hebei Provincial Department of Science and Technology NCP Prevention and Control Emergency Scientific Research Project (Grant no. 20277708D), played the role in “funding acquisition” as to direct this government funding for the study.
8. This research retained a third-party CRO company to monitor the data acquisition and to ensure the quality of data.
9. Other authors declare that they have no conflict of interest.